Viatris downsizes; Biovectra partners with Acuitas; Pfizer’s Hospira recalls injections; WuXi secures two new deals

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls, and more.

This week we saw mul­ti­ple CD­MO lead­er­ship ap­point­ments, as well as Biovec­tra ac­cess­ing Acuitas Ther­a­peu­tics’ tech­nol­o­gy to de­vel­op ther­a­pies at its new fa­cil­i­ty in Cana­da.

We al­so ze­ro in on Vi­a­tris sell­ing parts of its busi­ness in a move that will have it fo­cused as an eye care com­pa­ny, as well as WuXi Bi­o­log­ics se­cur­ing two sep­a­rate deals with Phar­maEssen­tia and IMIDomics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.